Saturday 17 October 2026
Export DTIL’s income statement to Excel — free account
Precision BioSciences, Inc.
DTIL Healthcare Biotechnology
Precision BioSciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $34.3 million, down 50.1% from fiscal 2024. In the quarter to June 2026, revenue grew 37,272.4%, EPS grew 40.9%, free cash flow grew 33.7% and total debt was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.
5.77
0.40
−6.48%
Follow DTIL
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | 3.01 | 1.56 | 93.46 | |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
— | (11.35) | (4.74) | (4.27) | |
P/B ratio |
— | 1.78 | 0.58 | 3.92 | |
Price to Tangible BV |
— | 1.81 | 0.59 | 4.17 | |
EV/Sales |
— | 1.26 | (1.16) | 61.23 | |
EV/EBITDA |
— | 0.00 | 0.80 | 0.00 | |
EV/Operating CF |
— | (0.97) | 0.60 | (0.58) | |
EV/FCF |
— | (0.96) | 0.60 | (0.58) | |
Quick Ratio |
12.26 | 13.56 | 12.97 | 2.99 | |
Current Ratio |
12.82 | 14.02 | 13.32 | 3.45 | |
Net Debt/EBITDA |
3.51 | 9.34 | (7.07) | 1.11 | |
Debt/Assets |
17.81% | 15.58% | 14.51% | 23.93% | |
Debt/Equity |
0.50 | 0.29 | 0.24 | 1.35 | |
Asset Turnover |
0.00 | 0.34 | 0.24 | 0.01 | |
Operating CF/Net income |
0.41 | 0.65 | (0.56) | 0.70 | |
Capex/Depreciation |
0.00 | (0.18) | (0.48) | 0.04 | |
Interest Coverage |
(63.87) | (29.18) | 35.94 | (57.09) | |
Research and Development Expense of Revenue |
0.00% | 120.96% | 42.29% | 102,707.69% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 62.77% | 21.14% | 56,369.23% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
0.00% | 14.29% | 5.97% | 18,353.85% | |
Graham Net Nets |
— | 0.30 | 1.06 | (0.39) | |
Graham Number |
— | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
— | (66.55%) | (123.08%) | (152.17%) | |
Free Cash Flow Yield |
— | (43.67%) | (124.59%) | (112.95%) | |
Revenue per Share |
0.00 | 0.44 | 2.67 | 0.00 | |
Operating CF per Share |
(0.52) | (0.48) | (0.88) | (1.29) | |
Capex per Share |
0.00 | 0.00 | (0.03) | 0.00 | |
Free Cash Flow per Share |
(0.52) | (0.49) | (0.90) | (1.29) | |
Cash per Share |
3.39 | 4.11 | 9.01 | 3.80 | |
Shareholders Equity per Share |
1.75 | 3.09 | 7.19 | 1.41 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.75 | 3.09 | 7.19 | 1.41 | |
Free Cash Flow |
(13.44) | (12.05) | (11.57) | (15.25) | |
Working Capital |
84.41 | 100.94 | 109.83 | 36.71 | |
Capital Expenditures |
0.00 | (0.11) | (0.32) | 0.02 | |
Net Current Asset Value |
10.92 | 40.90 | 56.57 | (25.17) | |
EV/EBIT |
— | 0.00 | 0.76 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.01 | (1.31) | |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | 2.09 | — | 0.11 | |
Average Payables |
0.97 | 0.93 | 0.80 | 1.15 | |
Average Assets |
117.42 | 134.15 | 145.40 | 123.38 | |
Average Common Equity |
39.67 | 62.72 | 74.32 | 40.75 |
Columns are period end dates